Yifeng Pharmary(603939)2025-04-28 14:55Financial Performance - The company's operating revenue for Q1 2025 was CNY 6,009,043,521.27, representing a year-on-year increase of 0.64% compared to CNY 5,970,923,210.35 in the same period last year[4] - Net profit attributable to shareholders of the listed company reached CNY 449,493,528.80, marking a 10.51% increase from CNY 406,753,106.09 in the previous year[4] - Basic earnings per share rose to CNY 0.37, up 12.12% from CNY 0.33 in the previous year[4] - Net profit for Q1 2025 was ¥493,549,281.07, up 10.6% from ¥445,951,883.35 in Q1 2024[25] - Earnings per share (EPS) increased to ¥0.37 in Q1 2025 from ¥0.33 in Q1 2024, representing a growth of 12.1%[25] - The company reported an operating profit of ¥650,541,861.92, which is an increase from ¥593,522,472.65 in the previous year, reflecting a growth of 9.6%[24] Cash Flow - The net cash flow from operating activities significantly increased by 71.42%, amounting to CNY 1,114,385,691.58 compared to CNY 650,107,205.26 in the same period last year[4] - Cash inflow from operating activities totaled $6,700,021,854.84, an increase of 8.1% compared to $6,196,262,045.28 in the previous period[28] - The net cash flow from operating activities was $1,114,385,691.58, a significant increase from $650,107,205.26 in the prior period[28] - Total cash outflow for operating activities was $5,585,636,163.26, slightly up from $5,546,154,840.02 in the previous period[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 27,786,561,356.06, a decrease of 0.67% from CNY 27,974,736,950.35 at the end of the previous year[5] - The equity attributable to shareholders of the listed company increased by 4.28%, reaching CNY 11,185,232,095.24 compared to CNY 10,725,687,023.42 at the end of the previous year[5] - The company's total liabilities decreased to ¥15,893,358,192.95 from ¥16,581,173,472.42, a reduction of approximately 4.15%[20] - The total current liabilities decreased to RMB 12,103,474,750.82 from RMB 12,598,073,700.81, indicating a reduction of about 3.9%[19] - The company's long-term assets totaled RMB 11,911,046,281.79, down from RMB 12,118,954,736.84, reflecting a decrease of approximately 1.7%[19] Inventory and Receivables - The accounts receivable decreased to RMB 1,831,522,834.46 from RMB 2,123,984,911.43, showing a decline of approximately 13.8%[18] - Inventory levels decreased to RMB 4,371,628,158.53 from RMB 4,528,102,252.16, a reduction of about 3.5%[18] - The company accelerated the collection of accounts receivable, contributing to the significant increase in cash flow from operating activities[9] - The company reported a significant increase in other receivables, rising to RMB 556,953,713.36 from RMB 477,936,663.36, an increase of about 16.4%[18] Store Operations - The company opened 94 new stores in Q1 2025, including 26 self-built stores and 68 franchise stores, while closing 84 stores, resulting in a net increase of 10 stores, totaling 14,694 stores[14] Investment Income - The company reported an investment income of CNY 27,186,162.03, which is related to its daily operating activities[8] - The company’s investment income rose to ¥27,186,162.03 from ¥14,930,288.87, indicating an increase of approximately 81.5%[24] Other Financial Metrics - Non-recurring gains and losses for the period amounted to CNY 11,508,186.24 after tax and minority interests[7] - Other comprehensive income after tax for Q1 2025 was ¥9,609,750.00, a significant recovery from a loss of ¥44,204,850.00 in Q1 2024[25] - The weighted average return on net assets was 4.02%, slightly down from 4.06% in the previous year[5] - The company's cash and cash equivalents increased to RMB 3,964,045,471.35 from RMB 3,578,925,577.22, reflecting a growth of approximately 10.8%[18] - The company maintained a stable goodwill value of RMB 4,768,942,152.07, unchanged from the previous period[19]